GSK’s latest phase III shingles trial offers hope to stem cell transplant patients – Proactive Investors UK
Proactive Investors UK |
GSK's latest phase III shingles trial offers hope to stem cell transplant patients
Proactive Investors UK The ZOE-HSCT phase III study tested the vaccine on adults over the age of 18 who had just undergone autologous haematopoietic stem cell transplant (auHSCT). It succeeded in its primary objective, demonstrating that Shingrix reduced the chances of … GSK: Phase III Data Supports Efficacy Of Shingrix In Preventing Shingles |
